Latest news with #CGOncology
Business Insider
15-05-2025
- Business
- Business Insider
Analysts Are Bullish on These NA Stocks: American Healthcare REIT, Inc. (AHR), CG Oncology, Inc. (CGON)
There's a lot to be optimistic about in the NA sector as 2 analysts just weighed in on American Healthcare REIT, Inc. (AHR – Research Report) and CG Oncology, Inc. (CGON – Research Report) with bullish sentiments. Confident Investing Starts Here: American Healthcare REIT, Inc. (AHR) RBC Capital analyst Michael Carroll maintained a Buy rating on American Healthcare REIT, Inc. on May 13 and set a price target of $39.00. The company's shares closed last Wednesday at $34.19. According to Carroll is a 5-star analyst with an average return of 7.4% and a 59.6% success rate. Carroll covers the NA sector, focusing on stocks such as Easterly Government Properties, Diversified Healthcare Trust, and First Industrial Realty. American Healthcare REIT, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $37.00, representing a 7.7% upside. In a report issued on April 28, Jefferies also initiated coverage with a Buy rating on the stock with a $37.00 price target. CG Oncology, Inc. (CGON) RBC Capital analyst Gregory Renza maintained a Buy rating on CG Oncology, Inc. on May 13 and set a price target of $68.00. The company's shares closed last Wednesday at $24.17, close to its 52-week low of $23.91. According to Renza is a 4-star analyst with an average return of 7.7% and a 40.3% success rate. Renza covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Verrica Pharmaceuticals, and ACADIA Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for CG Oncology, Inc. with a $60.25 average price target, implying a 150.1% upside from current levels. In a report issued on May 2, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $41.00 price target.
Yahoo
13-05-2025
- Business
- Yahoo
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.36 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -15.38%. A quarter ago, it was expected that this company would post a loss of $0.41 per share when it actually produced a loss of $0.48, delivering a surprise of -17.07%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. CG Oncology, Inc. , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.05 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 90.19%. This compares to year-ago revenues of $0.53 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. CG Oncology, Inc. Shares have lost about 12.3% since the beginning of the year versus the S&P 500's decline of -0.6%. While CG Oncology, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for CG Oncology, Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.53 on $0.53 million in revenues for the coming quarter and -$1.81 on $8.24 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Atara Biotherapeutics (ATRA), another stock in the same industry, has yet to report results for the quarter ended March 2025. This drug developer is expected to post quarterly loss of $3.07 per share in its upcoming report, which represents a year-over-year change of +46.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Atara Biotherapeutics' revenues are expected to be $0.2 million, down 99.3% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CG Oncology, Inc. (CGON) : Free Stock Analysis Report Atara Biotherapeutics, Inc. (ATRA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
29-04-2025
- Business
- Yahoo
Why CG Oncology, Inc. (CGON) Surged on Monday
We recently published an article titled . In this article, we are going to take a look at where CG Oncology, Inc. (NASDAQ:CGON) stands against the other stocks. The stock market kicked off the trading week on a mixed note, with two major indices ending in the green, as investors continued to digest more corporate earnings results. Among the bellwether indices, only the Nasdaq ended in the red, dropping 0.10 percent. In contrast, the Dow Jones grew by 0.28 percent and the S&P 500 inched up by 0.06 percent. Meanwhile, 10 companies mirrored a broader market optimism, as investors snapped up shares ahead of their first-quarter earnings performance in the next few days. To come up with the list, we considered only the companies with a $2-billion market capitalization and $5-million trading volume. A research doctor, looking intently at their microscope as they try to decipher the mysteries of immuno-oncology. CG Oncology, Inc. (NASDAQ:CGON) grew its share prices for a fifth straight day on Monday, surging 25.03 percent to end at $27.97 apiece as investors cheered the promising results of its bladder cancer treatment that could rival Johnson & Johnson's. Following a two-year study, CG Oncology, Inc. (NASDAQ:CGON) said that cretostimogene grenadenorepvec—its investigational monotherapy for high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to BCG treatment— reported a robust 42.3 percent response rate and 97.3 percent non-progression to muscle-invasive disease. Additionally, 91.6 percent of the enrollees retained their ability to avoid cystectomy. The treatment, which could rival Johnson & Johnson's own bladder cancer treatment, demonstrated a high degree of safety without adverse effects reported. Following the announcement, Cantor Fitzgerald reiterated its Overweight rating for CG Oncology, Inc. (NASDAQ:CGON) alongside a price target of $75, or a 168-percent upside from its latest closing price. Overall CGON ranks 2nd on our list of the best performing stocks on Monday. While we acknowledge the potential of CGON as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than CGON but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Insider
29-04-2025
- Business
- Business Insider
CG Oncology Stock (CGON) Surges 25% As Cancer Drug Shows Remarkable Results
CG Oncology (CGON) shares rocketed 25% higher on Monday, with trading volume exploding as investors responded enthusiastically to newly released clinical trial data. The biotech company, focused on developing innovative bladder cancer treatments, has now enjoyed four consecutive days of gains, climbing over 34% over the past week. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. The dramatic price surge follows the company's presentation of highly promising clinical trial results at the American Urological Association Annual Meeting this past weekend. Breakthrough Results in Bladder Cancer Treatment The excitement centers around CG Oncology's lead drug candidate, cretostimogene grenadenorepvec, which demonstrated exceptional effectiveness in treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The Phase 3 BOND-003 trial revealed a 42.3% complete response rate at the 24-month mark, significantly higher than previous treatment options for this difficult-to-treat condition. Perhaps most impressive, 97.3% of patients receiving the treatment remained free from progression to muscle-invasive bladder cancer after two years. The drug also maintained a strong safety profile, with researchers reporting no serious treatment-related adverse events among trial participants. 'These results represent best-in-disease durability data,' noted clinical investigators at the conference, highlighting the potential transformative impact for patients who currently have limited treatment options and often face the prospect of complete bladder removal. Market Implications and Analyst Response With Monday's close, CGON stock has nearly doubled from its January IPO price, signaling strong investor confidence in its innovative approach to bladder cancer treatment. Wall Street has also responded favorably to the news, with analysts maintaining a consensus 'Strong Buy' rating on CG Oncology's shares. The average price target for CGON stock is $61.00, representing a potential upside of 118.09% from current levels. The strong clinical data suggests a reduced regulatory risk and increased likelihood of eventual FDA approval, a critical milestone for any biotech company. Institutional interest has grown alongside the positive clinical results, with 90 institutions recently adding to their CGON positions, though some insider selling has occurred over the past six months. Looking Ahead The market reaction reflects growing confidence that cretostimogene could become a preferred treatment option in a substantial and growing market. With bladder cancer ranking as one of the most expensive cancers to treat, a breakthrough therapy could generate significant revenue. Nevertheless, the impressive durability and efficacy data position CG Oncology favorably against competitors in the space. If regulatory progress continues smoothly, analysts expect further upward revisions to revenue projections and potentially additional price appreciation for this emerging player in the oncology treatment landscape.
Business Insider
28-04-2025
- Health
- Business Insider
CG Oncology announces Phase 3 BOND-003 data presented at AUA meeting
CG Oncology (CGON) announced that cretostimogene grenadenorepvec monotherapy data was presented at the Practice-Changing, Paradigm-Shifting Clinical Trials in Urology Plenary Session at the 2025 American Urological Association, AUA, Annual Meeting, in Las Vegas, Nevada. The Phase 3 BOND-003 Cohort C study is in patients with high-risk non-muscle invasive bladder cancer, NMIBC, unresponsive to Bacillus Calmette Guerin, BCG, treatment with carcinoma in situ with or without Ta or T1 disease. The study reported 75.5% complete response at any time, with 34 confirmed CRs at 24 months and 9 patients pending their 24-month assessment as of the cutoff date of March 14, 2025. The 12- and 24-month CR rates are 50.7% and 42.3% by K-M estimation, respectively. Median duration of response, DOR, is 28 months and is ongoing. Notably, 97.3% of patients were free from progression to muscle invasive disease at 24 months.
